In conclusion, our data demonstrated for the first time that GSK-343, an EZH2 inhibitor, could be considered a promising therapeutic strategy for the management of PD thanks its abilities to counteract neuroinflammation as well as apoptosis processes in PD. This evidence concerns the gene EZH2 and Parkinson disease.